These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38290412)

  • 1. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Wehn AK; Qiu P; Lunceford J; Yarunin A; Cristescu R; Liu L; Roessler K; Bilke S; Day JR; Timms KM; Weichert W; Marton MJ
    Gynecol Oncol; 2024 May; 184():67-73. PubMed ID: 38290412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
    Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
    Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
    Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
    Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
    J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M
    Gynecol Oncol; 2024 Aug; 187():221-226. PubMed ID: 38821039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
    Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
    JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Roma C; Esposito Abate R; Sacco A; Califano D; Arenare L; Bergantino F; Pisano C; Cecere SC; Scambia G; Lorusso D; Artioli G; Tasca G; Spina A; Russo D; Gadducci A; De Angelis C; Bologna A; Marchini S; Capoluongo ED; Perrone F; Pignata S; Normanno N
    Eur J Cancer; 2024 Jul; 206():114127. PubMed ID: 38797038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
    Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
    Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
    Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
    Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
    Morgan RD; Clamp AR; Barnes BM; Timms K; Schlecht H; Yarram-Smith L; Wallis Y; Valganon-Petrizan M; MacMahon S; White R; Morgan S; McKenna S; Hudson E; Tookman L; George A; Manchanda R; Sundar SS; Nicum S; Brenton JD; Kristeleit RS; Banerjee S; McNeish IA; Ledermann JA; Taylor SS; Evans DGR; Jayson GC
    Int J Gynecol Cancer; 2023 Aug; 33(8):1253-1259. PubMed ID: 37072323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.
    Fountzilas E; Papadopoulou K; Chatzikonstantinou T; Karakatsoulis G; Constantoulakis P; Tsantikidi A; Tsaousis G; Karageorgopoulou S; Koumarianou A; Mauri D; Ntavatzikos A; Saridaki Z; Petrakis G; Fostira F; Fountzilas G; Liontos M
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
    Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
    Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
    Scaglione GL; Pignata S; Pettinato A; Paolillo C; Califano D; Scandurra G; Lombardo V; Di Gaudio F; Pecorino B; Mereu L; Scollo P; Capoluongo ED
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
    Kekeeva T; Andreeva Y; Tanas A; Kalinkin A; Khokhlova S; Tikhomirova T; Tyulyandina A; Popov A; Kuzmenko M; Volkonsky M; Chernorubashkina N; Saevets V; Dmitriev V; Nechushkina V; Vedrova O; Andreev S; Kutsev S; Strelnikov V
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Boidot R; Blum MGB; Wissler MP; Gottin C; Ruzicka J; Chevrier S; Delhomme TM; Audoux J; Jeanniard A; Just PA; Harter P; Pignata S; González-Martin A; Marth C; Mäenpää J; Colombo N; Vergote I; Fujiwara K; Duforet-Frebourg N; Bertrand D; Philippe N; Ray-Coquard I; Pujade-Lauraine E;
    Eur J Cancer; 2024 May; 202():113978. PubMed ID: 38471290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.